Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Snags More Than $3.1M in Grants for EU-, UK-Sponsored Research Initiatives

Premium

Proteomics firm Cellzome said this week it has won more than €2.3 million ($3.1 million) in grants funding its participation in three separate research projects.

The funding supports Cellzome’s work in: Blueprint, an EU-funded effort to analyze the epigenome of the hematopoietic system; Orchid, an EU-funded project in which Cellzome will work under the direction of drugmaker GlaxoSmithKline to identify new drug targets in tuberculosis; and a stem cell characterization project the company has undertaken in collaboration with Pfizer, the University of Sheffield, and the stem cell firm Plasticell (see story this issue).

The company will receive €1.2 million for its work on the Blueprint project, €1.1 million for its stem cell research, and an undisclosed amount for its participation in the Orchid project, which, according to Cellzome chief scientific officer David Simmons, will be centered at GSK’s “Open Lab” in Tres Cantos, Spain.

Cellzome will be using its Episphere and Kinobeads chemoproteomics platforms in these projects, as well as mass spec-based proteome-wide screening methods.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.